Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Fallopian Tube Endometrioid Adenocarcinoma
Explore 23 assets in Fallopian Tube Endometrioid Adenocarcinoma →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06639074CT.gov Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial | — | Recruiting | — | — | — |
NCT05920798CT.gov Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Endometrioid Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine (this asset) | Mayo Clinic | P2 | B · 58 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BB |
| Olaparib | NRG Oncology | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Ohio State University Comprehensive Cancer Center | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | B |
| Adriamycin | National Cancer Institute (NCI) | P2/3 | B |
| Nogitecan | National Cancer Institute (NCI) | P2/3 | B |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | B |
| Cediranib | National Cancer Institute (NCI) | P2/3 | B |
+21 more in the Fallopian Tube Endometrioid Adenocarcinoma cohort
Other indications for Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Endometrioid Adenocarcinoma | — | P2 | BB · 65 |
| Fallopian Tube Serous Adenocarcinoma | — | P2 | BB · 65 |
| Primary Peritoneal Serous Adenocarcinoma | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine in Fallopian Tube Endometrioid Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/multi-epitope-folate-receptor-alpha-loaded-dendritic-cell-vaccine-fallopian-tube-endometrioid-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →